July 7 (Reuters) - The U.S. Food and Drug Administration
approved KalVista Pharmaceuticals' ( KALV ) drug for a type of
hereditary swelling disorder, the company said on Monday.
(Reporting by Puyaan Singh in Bengaluru; Editing by Arun
Koyyur)